Combining immunotherapy and AlphaFold to improve outcomes in oral squamous cell carcinoma (OSCC) treatment

Puntos clave

• Improved outcomes in oral squamous cell carcinoma highlight a potential enhancement from combining immunotherapy and AlphaFold.
• Key evidence includes specific tumor antigens identified through AlphaFold, which may heighten immunotherapy efficacy.
• Analysis leverages artificial intelligence to improve the specificity of treatment approaches for oral squamous cell carcinoma.
• This combination may enable more effective targeting of therapies, addressing unmet needs in cancer treatment.